Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria

Journal of Endourology

Volumn 19, Issue 3, 2005, Pages 429-432

  Dolin, Daniele J ^a   Asplin, John R ^b   Flagel, Leigh ^b   Grasso, Michael ^a   Goldfarb, David S ^a,c  

^a ST VINCENT S HOSPITAL   (United States)

^b LithoLink Corporation   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CYSTINE; CYSTINE BINDING THIOL DRUG; PENICILLAMINE; THIOL DERIVATIVE; TIOPRONIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINIZATION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CLINICAL ARTICLE; CYSTINURIA; DOSE RESPONSE; DRUG MONITORING; FEMALE; FLUID INTAKE; HUMAN; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; URINARY EXCRETION; URINE PH; URINE VOLUME;

ADMINISTRATION, ORAL; ADULT; CAPTOPRIL; CASE-CONTROL STUDIES; CYSTEINE; CYSTINURIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PENICILLAMINE; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; THIOPRONINE; TREATMENT OUTCOME; URINALYSIS;

EID: 18544377340     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2005.19.429     Document Type: Article

References (15)

1. Palacin M, Borsani G, Sebastio G. The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev 2001;11:328-335.
2. Ng CS, Streem SB. Medical and surgical therapy of the cystine stone patient. Curr Opin Urol 2001;11:353-358.
3. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: An update of a 1980 protocol. Am J Med 1995;98:50-59.
4. Goldfarb DS. Cystinuria. In: Nature Encyclopedia of Life Sciences. London: Nature Publishing Group, 2000.
5. Menon M, Resnick MI. Urinary lithiasis: Etiology, diagnosis and medical management. In: Walsh PC, Retik AB, Vaughn ED Jr, Wein AJ (eds): Campbell's Urology, ed 8. Philadelphia: WB Saunders, 2002, p 3243.
6. Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 2001;166:688-693.
7. Goldfarb DS, Asplin JR, Clark C, Parks JH, Coe FL. Cystine supersaturation measurements in patients taking cystine-binding thiol drugs [abstract]. J Am Soc Nephrol 2001;12:753A.
8. Pak CY, Fuller CJ. Assessment of cystine solubility in urine and of heterogeneous nucleation. J Urol 1983;129:1066-1070.
9. Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol 2000;164:1481-1485.
10. Dent CE, Senior B. Studies on the treatment of cystinuria. Br J Urol 1955;27:317-322.
11. Daudon M, Cohen-Solal F, Barbey F, Gagnadoux MF, Knebelmann B, Jungers P. Cystine crystal volume determination: A useful tool in the management of cystinuric patients. Urol Res 2003;31:207-211.
12. Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionyl-glycine. J Urol 1986;136:1003-1008.
13. Koide T, Kinoshita K, Takemoto M, Yachiku S, Sonoda T. Conservative treatment of cystine calculi: Effect of oral alpha-mercaptopropionylglycine on cystine stone dissolution and on prevention of stone recurrence. J Urol 1982;128:513-516.
14. Chow GK, Streem SB. Medical treatment of cystinuria: Results of contemporary clinical practice. J Urol 1996;156:1576-1578.
15. Tiopronin for cystinuria. Med Lett Drugs Ther 1989;31:7-8.